PMID- 34446063
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210830
IS  - 1758-5996 (Print)
IS  - 1758-5996 (Electronic)
IS  - 1758-5996 (Linking)
VI  - 13
IP  - 1
DP  - 2021 Aug 26
TI  - Association between dipeptidyl peptidase-4 inhibitors use and leptin in type 2 
      diabetes mellitus.
PG  - 88
LID - 10.1186/s13098-021-00703-x [doi]
LID - 88
AB  - BACKGROUND: Dipeptidyl peptidase-4 inhibitors (DPP-4i) provide a unique 
      antihyperglycemic effect by regulating incretin peptides in type 2 diabetes 
      mellitus (T2DM) patients who are inadequately controlled with insulin therapy. 
      The aim of this study was to investigate the impact of DPP-4i on leptin 
      concentrations in subjects with T2DM. METHODS: Randomized controlled trials 
      (RCTs) with comparators were systematically searched through PubMed, Embase, 
      and the Cochrane Library. Quantitative analysis was performed with a fixed or 
      random-effects model according to heterogeneity. Publication bias was evaluated 
      by using the standard methods for sensitivity analysis. RESULTS: Ten trials with 
      698 patients with T2DM were included. Pooled analysis demonstrated that DPP-4i 
      did not significantly change leptin concentrations (1.31 ng/mL, 95 % CI - 0.48 to 
      3.10). DPP-4i exerted effects on modulating leptin levels compared to active 
      comparators (0.21 ng/mL, 95 % CI - 1.37 to 1.78). Meta-analysis was powerful and 
      stable after sensitivity analysis. CONCLUSIONS: DPP-4i did not modulate leptin 
      concentrations in T2DM and exerted no stronger effects than traditional 
      antidiabetic agents.
CI  - (c) 2021. The Author(s).
FAU - Wei, Xin
AU  - Wei X
AD  - Department of Cardiology and Macrovascular Disease, Beijing Tiantan Hospital, 
      Capital Medical University, Beijing, China.
FAU - Bai, Yu
AU  - Bai Y
AD  - Department of Otolaryngology, Beijing Haidian Hospital, Beijing, China.
FAU - Wang, Zhuo
AU  - Wang Z
AD  - Department of Gastroenterology, Beijing Tiantan Hospital, Capital Medical 
      University, Beijing, China.
FAU - Zheng, Xiaohong
AU  - Zheng X
AD  - Department of Neuro-Oncology, Cancer Center, Beijing Tiantan Hospital, Capital 
      Medical University, Beijing, China.
FAU - Jin, Zening
AU  - Jin Z
AD  - Department of Cardiology and Macrovascular Disease, Beijing Tiantan Hospital, 
      Capital Medical University, Beijing, China. jinzeningttyy@163.com.
FAU - Liu, Xin
AU  - Liu X
AD  - Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China. liuxinmj@aliyun.com.
LA  - eng
GR  - the key specialty of beijing/the key specialty of beijing/
PT  - Journal Article
DEP - 20210826
PL  - England
TA  - Diabetol Metab Syndr
JT  - Diabetology & metabolic syndrome
JID - 101488958
PMC - PMC8390252
OTO - NOTNLM
OT  - Dipeptidyl peptidase-4 inhibitors
OT  - Leptin
OT  - Randomized controlled trials
OT  - Type 2 diabetes mellitus
COIS- The authors declare that they have no competing interests.
EDAT- 2021/08/28 06:00
MHDA- 2021/08/28 06:01
PMCR- 2021/08/26
CRDT- 2021/08/27 05:41
PHST- 2021/05/20 00:00 [received]
PHST- 2021/08/02 00:00 [accepted]
PHST- 2021/08/27 05:41 [entrez]
PHST- 2021/08/28 06:00 [pubmed]
PHST- 2021/08/28 06:01 [medline]
PHST- 2021/08/26 00:00 [pmc-release]
AID - 10.1186/s13098-021-00703-x [pii]
AID - 703 [pii]
AID - 10.1186/s13098-021-00703-x [doi]
PST - epublish
SO  - Diabetol Metab Syndr. 2021 Aug 26;13(1):88. doi: 10.1186/s13098-021-00703-x.